| Provenge (sipuleucel-T) / Bausch Health |
NCT01832870: Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer |
|
|
| Completed | 1 | 9 | US | sipuleucel-T, Provenge, ipilimumab, Yervoy | Prostate Oncology Specialists, Inc. | Prostate Cancer, Castrate Resistant Prostate Cancer | 02/16 | 02/16 | | |
NCT02036918: Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer |
|
|
| Completed | 1 | 20 | US | Sipuleucel-T, Provenge, Lymph Node Biopsy, lymphadenectomy, lymph node dissection, excisional lymph node biopsy | Duke University | Prostate Cancer | 02/19 | 02/19 | | |
NCT03024216: Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer |
|
|
| Completed | 1 | 37 | US | Atezolizumab1200 mg IV, Sipuleucel-T | University of Hawaii, Genentech, Inc., Dendreon | Prostate Cancer Metastatic | 12/20 | 12/20 | | |
| Recruiting | 1 | 12 | US | Sipuleucel-T, PROVENGE | University of Oklahoma, Dendreon | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 11/24 | 11/24 | | |
